The DOI matches its Crossref record; 5 of the 5 references it cites were found in a registry or an index.
Insulin, somatotropic, and luteinizing hormone axes in lean and obese women with polycystic ovary syndrome: common and distinct features
Abstract
The basic tenet of this investigation was that obesity is not a prerequisite in the development of polycystic ovary syndrome (PCOS), as indicated by the fact that 50% of PCOS women are not obese. Further, obesity itself is a disease entity with the common manifestation of insulin resistance/hyperinsulinemia with PCOS. Given recent evidence that insulin and GH may have gonadotropin-augmenting effects, we have determined the common and distinguishing features of neuroendocrine-metabolic dysfunctions of lean [body mass index (BMI), < 23 kg/m2] and obese (BMI, > 30 kg/m2) women with the classical form of PCOS. Insulin sensitivity, as determined by rapid i.v. glucose tolerance testing; 24-h dynamics of insulin/glucose levels, somatotropic [GH/GH-binding protein/insulin-like growth factor I (IGF-I)/IGF-binding proteins (IGFBP)], and LH axes; and their downstream effects on ovarian steroids were simultaneously assessed in eight lean PCOS and eight obese PCOS patients and an equal number of BMI-matched normal cycling controls. Our results show that insulin sensitivity was reduced 50% (P < 0.01) in lean PCOS from that in lean controls. There was a further decrease in obese controls (P < 0.01) and a 2-fold greater reduction (P < 0.001) in obese PCOS than in obese controls, suggesting that insulin resistance (IR) is a common lesion in PCOS, and that obesity contributes an additional component to IR in obese PCOS. Consistent with the degree of IR, the manifestation of compensatory hyperinsulinemia in lean PCOS was incipient, being evident only in response to meals (P < 0.05), and became overt during the 24-h fasting/feeding phases of the day in obese control (P < 0.001) with a 2- to 3-fold greater elevation (P < 0.001) in obese PCOS. An enhanced early insulin response to glucose occurs equally in obese control (P < 0.01) and obese PCOS (P < 0.05), but not in their lean counterparts. Considering the more profound IR and the associated hyperglycemia in obese PCOS, the magnitude of the early insulin release is inadequate, suggesting that beta-cell dysfunction exists in obese PCOS. Remarkable differences in the somatotropic axis were also observed; although 24-h GH pulse frequency and levels of IGF-I and IGFBP-3 were unaltered by either PCOS or obesity, the 24-h mean GH pulse amplitude was increased by 30% (P < 0.01) in lean PCOS in the presence of normal levels of high affinity GHBP and normal GH response to GHRH. In distinct contrast, the somatotropic axis in both obese control and obese PCOS was profoundly modified, with attenuation of GH pulse amplitude (P < 0.001) and GH response to GHRH (P < 0.001), resulting in a state of hyposomatotropinism with a more than 50% reduction (P < 0.001) of 24-h mean GH levels. In addition, GHBP levels were elevated 2-fold and were correlated inversely with GH (r = -0.81) and positively with insulin (r = 0.75) concentrations. IGFBP-I levels were suppressed in both obese groups, with a 4-fold greater reduction in obese PCOS than that in obese controls. Thus, the downstream effects of hyperinsulinemia on the somatotropic axis may include up-regulation of hepatic production of GHBP, suppression of IGFBP-1 (r = 0.82) and sex hormone-binding globulin (r = -0.69) levels, and a more than 3-fold increase in ratios of IGF-I/IGFBP-1 and estradiol-testosterone/sex hormone-binding globulin, thereby increasing their bioavailabilities. In contrast, LH pulsatility was unaffected by obesity alone. An accelerated LH pulse frequency was evident in both lean and obese PCOS (P < 0.001), whereas the mean 24-h LH pulse amplitude was increased in lean (P < 0.001), but not obese, PCOS patients. These events resulted in a 3-fold increase in 24-h mean LH levels in lean PCOS and a 2-fold increase in obese PCOS. Thus, increased LH pulse frequency and augmented LH response to GnRH are characteristic of PCOS, independent of obesity, and the presence of obesity in PCOS is associated with an attenuated LH pulse amplitude, not accounted f
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Kiddy, D. S., Hamilton‐Fairley, D., Bush, A., Short, F., Anyaoku, V., Reed, M. J., & Franks, S. (1992) · Clinical Endocrinology · doi:10.1111/j.1365-2265.1992.tb02909.x · Cited by 921
Holte, J., Bergh, T., Berne, C., Wide, L., & Lithell, H. (1995) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.80.9.7673399 · Cited by 435
The role of hyperinsulinemia in the pathogenesis of ovarian hyperandrogenism
Wallach, E. E., Barbieri, R. L., Smith, S., & Ryan, K. J. (1988) · Fertility and Sterility · doi:10.1016/s0015-0282(16)60060-2 · Cited by 348
NESTLER, J. E., BARLASCINI, C. O., MATT, D. W., STEINGOLD, K. A., PLYMATE, S. R., CLORE, J. N., & BLACKARD, W. G. (1989) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem-68-6-1027 · Cited by 338
Cellular mechanisms of insulin resistance in polycystic ovarian syndrome
Ciaraldi, T. P. (1992) · Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.75.2.577 · Cited by 336
Cited by
Azziz, R., Carmina, E., Dewailly, D., Diamanti-Kandarakis, E., Escobar-Morreale, H. F., Futterweit, W., Janssen, O. E., Legro, R. S., Norman, R. J., Taylor, A. E., et al. (2009) · Fertility and Sterility · doi:10.1016/j.fertnstert.2008.06.035 · Cited by 2,132
Diamanti-Kandarakis, E., & Dunaif, A. (2012) · Endocrine Reviews · doi:10.1210/er.2011-1034 · Cited by 1,947
Legro, R. S., Arslanian, S. A., Ehrmann, D. A., Hoeger, K. M., Murad, M. H., Pasquali, R., & Welt, C. K. (2013) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2013-2350 · Cited by 1,919
Azziz, R., Carmina, E., Chen, Z., Dunaif, A., Laven, J. S. E., Legro, R. S., Lizneva, D., Natterson-Horowtiz, B., Teede, H. J., & Yildiz, B. O. (2016) · Nature Reviews Disease Primers · doi:10.1038/nrdp.2016.57 · Cited by 2,005
Tang, T., Lord, J. M., Norman, R. J., Yasmin, E., & Balen, A. H. (2012) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd003053.pub5 · Cited by 698
The effect of obesity on polycystic ovary syndrome: a systematic review and meta‐analysis
Lim, S. S., Norman, R. J., Davies, M. J., & Moran, L. J. (2013) · Obesity Reviews · doi:10.1111/j.1467-789x.2012.01053.x · Cited by 539
Tang, T., Glanville, J., Hayden, C. J., White, D., Barth, J. H., & Balen, A. H. (2006) · Human Reproduction · doi:10.1093/humrep/dei311 · Cited by 335
Lukanova, A., Lundin, E., Zeleniuch-Jacquotte, A., Muti, P., Mure, A., Rinaldi, S., Dossus, L., Micheli, A., Arslan, A., Lenner, P., et al. (2004) · European Journal of Endocrinology · doi:10.1530/eje.0.1500161 · Cited by 315
The origins and sequelae of abnormal neuroendocrine function in polycystic ovary syndrome
Blank, S. K., McCartney, C. R., & Marshall, J. C. (2006) · Human Reproduction Update · doi:10.1093/humupd/dml017 · Cited by 301
Silfen, M. E., Denburg, M. R., Manibo, A. M., Lobo, R. A., Jaffe, R., Ferin, M., Levine, L. S., & Oberfield, S. E. (2003) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2003-030617 · Cited by 269
Pastor, C. L., Griffin-Korf, M. L., Aloi, J. A., Evans, W. S., & Marshall, J. C. (1998) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.83.2.4604 · Cited by 263
Adiponectin levels in women with polycystic ovary syndrome: a systematic review and a meta-analysis
Toulis, K. A., Goulis, D. G., Farmakiotis, D., Georgopoulos, N. A., Katsikis, I., Tarlatzis, B. C., Papadimas, I., & Panidis, D. (2009) · Human Reproduction Update · doi:10.1093/humupd/dmp006 · Cited by 262
Dumesic, D. A., Akopians, A. L., Madrigal, V. K., Ramirez, E., Margolis, D. J., Sarma, M. K., Thomas, A. M., Grogan, T. R., Haykal, R., Schooler, T. A., et al. (2016) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2016-2586 · Cited by 222
Jeanes, Y. M., & Reeves, S. (2017) · Nutrition Research Reviews · doi:10.1017/s0954422416000287 · Cited by 194
Tsilchorozidou, T., Honour, J. W., & Conway, G. S. (2003) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2003-030240 · Cited by 155
McCartney, C. R., Prendergast, K. A., Blank, S. K., Helm, K. D., Chhabra, S., & Marshall, J. C. (2009) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2008-1252 · Cited by 116
The Genetics of Obesity Lessons for Polycystic Ovary Syndrome
LEGRO, R. S. (2000) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.2000.tb06230.x · Cited by 109
Obesity and Weight Loss in Polycystic Ovary Syndrome
Hoeger, K. (2001) · Obstetrics and Gynecology Clinics of North America · doi:10.1016/s0889-8545(05)70187-x · Cited by 103
Ibáñez, L., Ong, K., Ferrer, A., Amin, R., Dunger, D., & de Zegher, F. (2003) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2002-022002 · Cited by 100
Polycystic Ovary Syndrome in Adolescence
Blank, S. K., Helm, K. D., McCartney, C. R., & Marshall, J. C. (2008) · Annals of the New York Academy of Sciences · doi:10.1196/annals.1429.005 · Cited by 97
MENSTRUAL DISORDERS IN ADOLESCENTS
Gordon, C. M. (1999) · Pediatric Clinics of North America · doi:10.1016/s0031-3955(05)70135-8 · Cited by 92
The correlation of aromatase activity and obesity in women with or without polycystic ovary syndrome
Chen, J., Shen, S., Tan, Y., Xia, D., Xia, Y., Cao, Y., Wang, W., Wu, X., Wang, H., Yi, L., et al. (2015) · Journal of Ovarian Research · doi:10.1186/s13048-015-0139-1 · Cited by 118
“There is evidence that obesity, particularly abdominal obesity, exacerbates both the clinical and endocrine features of PCOS [23] which demonstrates significantly more serious insulin resistance in these individuals than normal-weight counterparts [24].”
BackgroundDurmus, U., Duran, C., & Ecirli, S. (2017) · Journal of Endocrinological Investigation · doi:10.1007/s40618-016-0582-x · Cited by 87
Georgopoulos, N. A., Saltamavros, A. D., Vervita, V., Karkoulias, K., Adonakis, G., Decavalas, G., Kourounis, G., Markou, K. B., & Kyriazopoulou, V. (2009) · Fertility and Sterility · doi:10.1016/j.fertnstert.2008.04.067 · Cited by 80
Kawwass, J. F., Sanders, K. M., Loucks, T. L., Rohan, L. C., & Berga, S. L. (2017) · Human Reproduction · doi:10.1093/humrep/dex086 · Cited by 79
Moret, M., Stettler, R., Rodieux, F., Gaillard, R. C., Waeber, G., Wirthner, D., Giusti, V., Tappy, L., & Pralong, F. P. (2009) · Neuroendocrinology · doi:10.1159/000160911 · Cited by 72
Polycystic Ovarian Syndrome: Long-Term Health Consequences
Zore, T., Joshi, N., Lizneva, D., & Azziz, R. (2017) · Seminars in Reproductive Medicine · doi:10.1055/s-0037-1603096 · Cited by 72
Naltrexone treatment in clomiphene resistant women with polycystic ovary syndrome
Ahmed, M. I., Duleba, A. J., El Shahat, O., Ibrahim, M. E., & Salem, A. (2008) · Human Reproduction · doi:10.1093/humrep/den273 · Cited by 58
High-fat high-sugar diet induces polycystic ovary syndrome in a rodent model†
Roberts, J. S., Perets, R. A., Sarfert, K. S., Bowman, J. J., Ozark, P. A., Whitworth, G. B., Blythe, S. N., & Toporikova, N. (2017) · Biology of Reproduction · doi:10.1095/biolreprod.116.142786 · Cited by 58
Reproductive neuroendocrine dysfunction in polycystic ovary syndrome: Insight from animal models
Roland, A. V., & Moenter, S. M. (2014) · Frontiers in Neuroendocrinology · doi:10.1016/j.yfrne.2014.04.002 · Cited by 57
Holte, J. (1998) · Journal of Endocrinological Investigation · doi:10.1007/bf03350784 · Cited by 52
THERAPY OF ENDOCRINE DISEASE: Treatment of hirsutism in the polycystic ovary syndrome
Pasquali, R., & Gambineri, A. (2014) · European Journal of Endocrinology · doi:10.1530/eje-13-0585 · Cited by 49
Is insulin resistance an essential component of PCOS?: The influence of confounding factors
Cibula, D. (2004) · Human Reproduction · doi:10.1093/humrep/deh137 · Cited by 43
Saadati, N., Haidari, F., Barati, M., Nikbakht, R., Mirmomeni, G., & Rahim, F. (2021) · Heliyon · doi:10.1016/j.heliyon.2021.e08338 · Cited by 34
Ovarian steroids modulate neuroendocrine dysfunction in polycystic ovary syndrome
Doi, S. A. R., Al-Zaid, M., Towers, P. A., Scott, C. J., & Al-Shoumer, K. A. S. (2005) · Journal of Endocrinological Investigation · doi:10.1007/bf03345319 · Cited by 26
Metadata
- Authors
- Morales, A. J.
- Venue
- Journal of Clinical Endocrinology & Metabolism
- Publisher
- The Endocrine Society
- Published
- 1996-08-01
- Volume
- 81
- Issue
- 8
- Pages
- 2854-2864
- ISSN
- 0021-972X (ISSN-L)
- OpenAlex
- W2078009607
- Cited by
- 455
- References
- 5
- FWCI
- 19.71
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.